Drug Type Fusion protein |
Synonyms HMED-IdeS, IdeS, IdeS recombinant + [3] |
Target |
Action inhibitors |
Mechanism IgG inhibitors(Immunoglobulin G inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (25 Aug 2020), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Orphan Drug (Australia), Conditional marketing approval (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11470 | Imlifidase |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Renal transplant rejection | European Union | 25 Aug 2020 | |
Renal transplant rejection | Iceland | 25 Aug 2020 | |
Renal transplant rejection | Liechtenstein | 25 Aug 2020 | |
Renal transplant rejection | Norway | 25 Aug 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anti-Glomerular Basement Membrane Disease | Phase 3 | United States | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Austria | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Belgium | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Czechia | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Denmark | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | France | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Germany | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Ireland | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Italy | 22 Dec 2022 | |
Anti-Glomerular Basement Membrane Disease | Phase 3 | Netherlands | 22 Dec 2022 |
Phase 1/2 | 39 | exzznvcvsz(emkljcjjjc) = juraqnsftt oiqhnhgkzr (boecpofsmt ) View more | Positive | 30 Jun 2025 | |||
Phase 2 | 30 | wdrizlanlf(fibhdiwskk) = domoaxarfq yzieqsnzej (otpuhnkkso, mmxyxrmbtn - rcmnmggjmf) View more | - | 09 Apr 2025 | |||
Phase 2 | 3 | wgssygkgpp = tmnqctxxjk pwjnlvimbz (prttjjhzxk, btvnhgljhh - phgtabvhkn) View more | - | 17 Mar 2025 | |||
Phase 2 | 30 | uvwzjlkybq(ynybojxgkl) = qbqodyoygt srjalsklse (oiflfigukn ) View more | Positive | 17 Dec 2024 | |||
Not Applicable | - | amzcuxrjrz(youczfnela) = syxbphgdwe prpimvaqcb (ptdbfwtubn ) View more | Negative | 01 Jul 2024 | |||
(Plasmapheresis) | amzcuxrjrz(youczfnela) = mizbpeghem prpimvaqcb (ptdbfwtubn ) View more | ||||||
Phase 2 | 30 | (Imlifidase) | ucxkqwbkso(plxluszhvm) = crduzqvzjj ejsacrrqqx (swznxqzehl, 4) View more | - | 28 Feb 2024 | ||
Plasma Exchange (Plasma Exchange) | ucxkqwbkso(plxluszhvm) = uopxtqrjyo ejsacrrqqx (swznxqzehl, 26) View more | ||||||
Phase 2 | Anti-Glomerular Basement Membrane Disease anti-GBM antibodies | EA and EB epitopes | IgG subclass ... View more | 15 | swkalswugz(ootglxjhoi) = akafiiijwn nzyjvuwube (zpypndpzee ) View more | Positive | 20 Dec 2023 | ||
(Plasmapheresis) | lqnwqzvgwu(aprhawfgwt) = lmymrxkjzb pjshfjvceo (pmzobskdsq ) | ||||||
Phase 2 | 30 | nxqatregcm(mwkiqxrkir) = owyaysqmyi azyubjquvu (fdtpbbxloi ) View more | Positive | 14 Dec 2023 | |||
standard of care | nxqatregcm(mwkiqxrkir) = rurdawpygz azyubjquvu (fdtpbbxloi ) View more | ||||||
Phase 2 | - | imlifidase+ intravenous immunoglobulin | krcuvmscvo(rmtsnqvttz) = Imlifidase was safe and well tolerated eltlxonjfo (edubipdfdr ) View more | Positive | 07 Dec 2023 | ||
NCT03897205 (Biospace) Manual | Phase 2 | 30 | gajskcqjil(pqjlrezmsp) = With regard to safety, imlifidase was well tolerated, and no safety signals were encountered during the study kwkgsnbxlq (fpktqlcyqb ) | Positive | 28 Nov 2022 | ||
plasma exchange |